Your Top 100 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
Luiz Paz-Ares, M.E.R. O'Brien, Muriel Mauer, Urania G. Dafni, Kersti Oselin, Libor Havel and 14 more
- Rank
- 63 of 3,616
- Percentile
- top 1.8%
- Where
- Annals of Oncology, 2022
- Citations
- 73
From the 2022 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.